Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Acta cir. bras ; 34(1): e20190010000007, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-983684

RESUMO

Abstract Purpose: To investigate the impact of Ramipril (RAM) on the expressions of insulin-like growth factor-1 (IGF-1) and renal mesangial matrix (RMM) in rats with diabetic nephropathy (DN). Methods: The Sprague Dawley rats were divided into normal control (NC) group (n = 12), DN group (n = 11), and DN+RAM group (n = 12). The ratio of renal weight to body weight (RBT), fasting blood glucose (FBG), HbA1c, 24-h urine protein (TPU), blood urea nitrogen (BUN), creatinine (Cr), renal pathological changes, the levels of IGF-1, fibronectin (FN), type IV collagen (Col-IV), and matrix metalloproteinases (MMP)-2 were compared among the groups. Results: Compared with NC group, the RBT, FBG, HbA1c, TPU, BUN, Cr, and RMM in DN group were significantly increased (P < 0.05), the IGF-1, FN, and Col-IV were significantly upregulated (P < 0.05), while MMP was significantly downregulated (P < 0.05). Compared with DN group, the indexes except for the FBG and HbA1c in DN+RAM group were significantly improved (P < 0.05), among which IGF-1 exhibited significant positive correlation with TPU(r=0.937), FN(r=0.896) and Col-IV(r=0.871), while significant negative correlation with MMP-2 (r=-0.826) (P<0.05). Conclusion: RAM may protect the kidneys by suppressing IGF-1 and mitigating the accumulation of RMM.


Assuntos
Animais , Masculino , Ratos , Fator de Crescimento Insulin-Like I/antagonistas & inibidores , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Ramipril/farmacologia , Nefropatias Diabéticas/tratamento farmacológico , Células Mesangiais/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/metabolismo , Imuno-Histoquímica , Fibronectinas/efeitos dos fármacos , Fibronectinas/metabolismo , Ratos Sprague-Dawley , Metaloproteinases da Matriz/efeitos dos fármacos , Metaloproteinases da Matriz/metabolismo , Colágeno Tipo IV/efeitos adversos , Colágeno Tipo IV/metabolismo , Nefropatias Diabéticas/metabolismo , Células Mesangiais/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA